A carregar...
Quantification of Expression of Antigens Targeted by Antibody Based Therapy in Chronic Lymphocytic Leukemia
Anti-CD20 (Rituximab), anti-CD52 (Alemtuzumab), anti-CD22 (BL22, HA22) and anti-CD25 (Oncotac) are mainstay therapeutic options or in pre-clinical development for the treatment of chronic lymphocytic leukemia (CLL). Studies suggest that levels of surface antigen expression may affect response to mon...
Na minha lista:
| Publicado no: | Am J Clin Pathol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4698892/ https://ncbi.nlm.nih.gov/pubmed/24225748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1309/AJCPYFQ4XMGJD6TI |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|